News

Aug 01,2022

Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company

Jul 14,2022

Dermaliq appoints Gordon Dow, PharmD, Michael Kuligowski, MD, PhD, R. Todd Plott, MD and Xavier Yon to its Dermatology Scientific and Medical Advisory Board

Apr 27,2022

OncoC4 Announces Fast Track Designation Granted by the U.S. FDA for ONC-392 Monotherapy in PD(L)1-Resistant NSCLC

Apr 12,2022

Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with Metastatic Melanoma Presented at the AACR Annual Meeting 2022

Apr 06,2022

Using AI-Based Image Enhancement to Reduce Brain MRI Scan Times and Improve SNR

Mar 31,2022

DR. YANG LIU ACKNOWLEDGED AS TOP 20 DYNAMIC CEOS OF 2022

Mar 19,2022

Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company

Mar 17,2022

ONCOC4 RECOGNIZED AS A TOP 10 IMMUNOTHERAPY SOLUTIONS PROVIDERS

End of content

No more pages to load

Next page